Erasca Faces Patent Infringement Allegations Regarding ERAS-0015

Erasca is facing patent infringement allegations from Revolution Medicines regarding its oncology candidate, ERAS-0015, which is claimed to infringe U.S. Patent No. 12,409,225. Erasca has responded by asserting that the allegations are without merit. ERAS-0015 is in development for RAS/MAPK pathway-driven cancers and has received Fast Track designation for pancreatic cancer.